Nektar Therapeutics (NKTR) EBT (2010 - 2026)

Nektar Therapeutics' EBT history runs 17 years deep, the most recent figure standing at -$43.1 million for Q1 2026.

• In Q1 2026, EBT rose 7.07% year-over-year to -$43.1 million; the TTM figure through Mar 2026 stood at -$152.2 million (down 18.24% YoY), while the FY2025 annual figure was -$155.5 million, down 30.44% from the prior year.
• EBT for Q1 2026 stood at -$43.1 million, down from -$34.7 million in the prior quarter.
• The five-year high for EBT was $7.0 million in Q4 2024, with the low at -$159.0 million in Q2 2022.
• The 5-year median for EBT is -$45.9 million (2023), against an average of -$56.4 million.
• The sharpest annual moves came in 2024 and 2025: EBT soared 116.63% in 2024, then tumbled 595.6% in 2025.
• Nektar Therapeutics' EBT stood at -$56.5 million in 2022, then grew by 25.53% to -$42.1 million in 2023, then surged by 116.63% to $7.0 million in 2024, then sank by 595.6% to -$34.7 million in 2025, then declined by 24.17% to -$43.1 million in 2026.
• Business Quant data shows NKTR's EBT at -$43.1 million in Q1 2026, -$34.7 million in Q4 2025, and -$35.0 million in Q3 2025.